MAOA expression in human prostate cancer biopsy shows increased expression with increasing cancer malignancy and demonstrates therapeutic target opportunity.
Clinical trial of MAO inhibitor demonstrated efficacy in patients with biochemical recurrent castrate-sensitive prostate cancer.
link to publication: https://www.nature.com/articles/s41391-020-0211-9
